Charles River Laboratorie... (CRL)

Review Charles River's (CRL) international revenue performance and how it affects the predictions of financial analysts on Wall Street and the future prospects for the stock.

Charles River Laboratories International, Inc. (NYSE:CRL ) Q2 2025 Earnings Conference Call August 6, 2025 9:00 AM ET Company Participants Flavia H. Pease - Corporate Executive VP & CFO James C.

Charles River Laboratories International Inc. CRL stock is trading lower on Wednesday after the company released second-quarter 2025 earnings.

Charles River Laboratories posted a strong Q2 beat, but results were boosted by one-time items and cost cuts that may not be sustainable. Ongoing risks include regulatory pressure to phase out animal ...

Although the revenue and EPS for Charles River (CRL) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall Str...

Charles River shares jump 9.3% pre-market after Q2 earnings and revenues beat estimates. The company raises its 2025 outlook.

Charles River Laboratories (CRL) came out with quarterly earnings of $3.12 per share, beating the Zacks Consensus Estimate of $2.5 per share. This compares to earnings of $2.8 per share a year ago.

Charles River Laboratories on Wednesday raised its annual profit forecast, betting on growing demand for its drug discovery and development services from drugmakers, sending its shares up more than 4%...

WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories Announces Second-Quarter 2025 Results.

Charles River (CRL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.